HOME >> BIOLOGY >> NEWS
Combination therapy drives cancer into remission

Researchers have achieved an experimental breakthrough in the simultaneous use of two or more agents for treating cancer, known as combination therapy. If it is shown to be safe and effective in humans, the therapy outlined by the new study is a promising general strategy for treating many cancers that do not respond to current therapies.

A two-drug combination therapy, published in tomorrow's issue of the journal Nature, led to the complete remission of a mouse model of B-cell lymphoma in all of the treated animals. In contrast, animals treated with either drug alone (rapamycin or doxorubicin) rarely experienced complete remission.

The study, led by Dr. Scott Lowe of Cold Spring Harbor Laboratory, establishes a new paradigm for overcoming chemotherapy resistance in many forms of cancer.

Rational Target Selection and an Off-the-Shelf Chemotherapeutic "One-Two Punch" for Lymphoma and Other Cancers

Pre-cancerous cells can be eliminated from the body by a natural self-destruct mechanism--normally active in many types of cells--called programmed cell death. Unfortunately, a hallmark of most cancers is a defect in programmed cell death that enables pre-cancerous cells to survive, proliferate out of control, and form a tumor.

Because most traditional chemotherapy agents act by triggering programmed cell death, such agents are frequently ineffective against tumors that lack a functional programmed cell death mechanism. Such tumors are said to be chemotherapy-resistant. The evasion of treatment-induced programmed cell death by chemotherapy-resistant tumors has been a major impediment to successful therapeutic outcomes for human cancer.

Lowe and his colleagues reasoned that--like a one-two knockout punch in boxing--using one drug to restore the programmed cell death mechanism and a second drug to trigger the process might reduce or eliminate chemotherapy-resistance and be an effective strategy for treating cancer.
'"/>

Contact: Jeff Picarello
picarell@cshl.edu
516-367-8486
Cold Spring Harbor Laboratory
17-Mar-2004


Page: 1 2 3 4

Related biology news :

1. Combination of gene therapy and gene silencing prevents neurodegenerative disease
2. Combination therapy dramatically improves function after spinal cord injury in rats
3. Combination drug therapy drastically reduces multiple coronary heart disease risk factors
4. Combination therapy improves anthrax survival
5. Drug Combination May Prove Effective To Prevent Recurrence Of Hepatitis C After Transplantation
6. Combination Therapy For Brain Tumors Holds Promise For Longer Survival After Surgery
7. New Heart-Attack Indicator Dramatically Improves Diagnostic Accuracy Of ER Doctors: TnT/Echocardiogram Combination Could Reduce Needless Admissions
8. Dangerous Chemical Combination Presents Possible Scenario For Gulf War Illnesses
9. Targeted therapy knocks out pediatric brain cancer in mice
10. New anti-inflammatory strategy for cancer therapy identified by UCSD researchers
11. Columbia research to examine gene influence on severity of peridontal disease, therapy response

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/16/2018)... ... October 15, 2018 , ... ... solutions for highly regulated industries, is a silver sponsor and exhibitor at the ... , The Biomanufacturing World Summit brings together the “who’s who” of ...
(Date:10/13/2018)... ... October 12, 2018 , ... ... host a booth at premier packaging event PACK EXPO International in Chicago from ... Manufacturers Institute (PMMI), of which HOLLOWAY AMERICA is a member. , At this ...
(Date:10/11/2018)... ... October 10, 2018 , ... ... newly diagnosed breast cancer patients to learn about their treatment options. The unique ... with triple negative breast cancer (TNBC), and was developed through a collaboration between ...
Breaking Biology News(10 mins):
(Date:10/11/2018)... ... October 11, 2018 , ... ... and software solutions, in collaboration with HP, the global leader in printing, has ... GHS Chemical Labels on all HP PageWide Printers. , The award-winning Avery UltraDuty ...
(Date:10/5/2018)... ... October 04, 2018 , ... ... along with Duke University, announced today at IDWeek™ 2018 the positive results of ... pathogen DNA in plasma, accurately identified causative pathogens in patients with infective endocarditis ...
(Date:10/5/2018)... ... October 04, 2018 , ... Earthres ... website that elevates the company’s brand identity and better reflects its current breadth ... broader range of engineering expertise and related support services to clients in seven ...
(Date:10/2/2018)... ... October 02, 2018 , ... ... for biopharmaceutical R&D, today announced a new out-of-the-box integration of the ... leading international pharmaceutical and laboratory equipment supplier. This enables the automatic import ...
Breaking Biology Technology:
Cached News: